This is not the most recent version of the article. View current version (7 DEC 2011)

Intervention Protocol

Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma

  1. Jian Hong Zhong2,
  2. Le Qun Li1,*,
  3. Liu Cheng Wu3

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 8 SEP 2010

Assessed as up-to-date: 4 JUL 2010

DOI: 10.1002/14651858.CD008713


How to Cite

Zhong JH, Li LQ, Wu LC. Lamivudine with or without adefovir dipivoxil for postoperative hepatocellular carcinoma (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 9. Art. No.: CD008713. DOI: 10.1002/14651858.CD008713.

Author Information

  1. 1

    Tumour Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, China

  2. 2

    First Affiliated Hospital, Guangxi Medical University, Department of Hepato-Biliary Diseases, Nanning, Guangxi, China

  3. 3

    First Affiliated Hospital, Guangxi Medical University, Colorectal and Anal Department, Nanning, Guangxi, China

*Le Qun Li, Tumour Affiliated Hospital, Guangxi Medical University, Nanning, Guangxi, 530021, China. xitongpingjia@163.com.

Publication History

  1. Publication Status: New
  2. Published Online: 8 SEP 2010

SEARCH

This is not the most recent version of the article. View current version (07 DEC 2011)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To study the benefits and harms of postoperative administration of lamivudine with or without adefovir dipivoxil in participants with surgically treated HCC and chronic hepatitis B virus infection or carrier state.